tiprankstipranks
Advertisement
Advertisement

JBIO Stock Latest News

Jade Biosciences price target raised to $45 from $35 at H.C. Wainwright
The FlyJade Biosciences price target raised to $45 from $35 at H.C. Wainwright
1d ago
JBIO
Jade Biosciences appoints Edward Conner as chief medical officer
PremiumThe Fly
Jade Biosciences appoints Edward Conner as chief medical officer
6d ago
ARDX
JBIO
Jade Biosciences Elevates Andrew King to R&D President
PremiumCompany Announcements
Jade Biosciences Elevates Andrew King to R&D President
6d ago
8K
JBIO
Jade Biosciences Adopts 2026 Employment Inducement Stock Plan
PremiumCompany Announcements
Jade Biosciences Adopts 2026 Employment Inducement Stock Plan
26d ago
8K
JBIO
Jade Biosciences price target raised to $35 from $25 at H.C. Wainwright
PremiumThe Fly
Jade Biosciences price target raised to $35 from $25 at H.C. Wainwright
1M ago
JBIO
Jade Biosciences participates in a conference call with William Blair
PremiumThe FlyJade Biosciences participates in a conference call with William Blair
1M ago
JBIO
3 High-Yield Dividend Stocks to Buy in Today’s Volatile Market, According to Analysts, 3/18/2026
Premium
Market News
3 High-Yield Dividend Stocks to Buy in Today’s Volatile Market, According to Analysts, 3/18/2026
1M ago
JBIO
TRIN
Jade Biosciences price target raised to $39 from $28 at BTIG
Premium
The Fly
Jade Biosciences price target raised to $39 from $28 at BTIG
1M ago
JBIO
Jade Biosciences price target raised to $23 from $17 at Guggenheim
PremiumThe Fly
Jade Biosciences price target raised to $23 from $17 at Guggenheim
2M ago
JBIO
Jade: Differentiated IgAN Profile and Multi-Asset Upside Make $2B Peak Sales for JADE101 Look Conservative
PremiumRatings
Jade: Differentiated IgAN Profile and Multi-Asset Upside Make $2B Peak Sales for JADE101 Look Conservative
2M ago
JBIO
Positioning Jade Biosciences as a Leading APRIL Inhibitor Play in IgA Nephropathy With Compelling Pipeline and Risk‑Reward
PremiumRatings
Positioning Jade Biosciences as a Leading APRIL Inhibitor Play in IgA Nephropathy With Compelling Pipeline and Risk‑Reward
2M ago
JBIO
Jade Biosciences price target raised to $40 from $19 at Stifel
PremiumThe Fly
Jade Biosciences price target raised to $40 from $19 at Stifel
2M ago
JBIO
Jade Biosciences initiated with an Outperform at LifeSci Capital
PremiumThe FlyJade Biosciences initiated with an Outperform at LifeSci Capital
2M ago
JBIO
Jade Biosciences reports Q4 EPS ($3.19), consensus ($2.95)
Premium
The Fly
Jade Biosciences reports Q4 EPS ($3.19), consensus ($2.95)
2M ago
JBIO
Jade Biosciences initiated with a Buy at H.C. Wainwright
Premium
The Fly
Jade Biosciences initiated with a Buy at H.C. Wainwright
4M ago
JBIO
Jade Biosciences Outlines 2026 Autoimmune Pipeline Priorities
PremiumCompany Announcements
Jade Biosciences Outlines 2026 Autoimmune Pipeline Priorities
4M ago
8K
JBIO
Jade Biosciences outlines key 2026 objectives, strategy
PremiumThe Fly
Jade Biosciences outlines key 2026 objectives, strategy
4M ago
JBIO
Jade Biosciences files to sell 3.21M shares of common stock for holders
PremiumThe Fly
Jade Biosciences files to sell 3.21M shares of common stock for holders
4M ago
JBIO
Jade Biosciences Announces Private Placement Agreement
PremiumCompany Announcements
Jade Biosciences Announces Private Placement Agreement
4M ago
8K
JBIO
Jade Biosciences prices 3.21M shares at $14.00 in private placement
PremiumThe FlyJade Biosciences prices 3.21M shares at $14.00 in private placement
4M ago
JBIO
Jade Biosciences initiated with a Buy at Clear Street
Premium
The Fly
Jade Biosciences initiated with a Buy at Clear Street
5M ago
JBIO
Jade Biosciences price target raised to $17 from $14 at Guggenheim
Premium
The Fly
Jade Biosciences price target raised to $17 from $14 at Guggenheim
5M ago
JBIO

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >